Skip to main content
Contact Us
Subscribe
E-Edition
31°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
79.02
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 8, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
378
Open
79.02
Bid (Size)
79.00 (1)
Ask (Size)
79.65 (1)
Prev. Close
79.02
Today's Range
79.02 - 79.02
52wk Range
72.87 - 89.74
Shares Outstanding
1,253,809,440
Dividend Yield
3.80%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
December 10, 2023
Regulators are already on the case, and their findings will have financial impacts.
Via
The Motley Fool
3 biotech powerhouses poised to thrive amid sector rebound
December 08, 2023
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.
Via
MarketBeat
Topics
ETFs
Performance
YTD
-7.46%
-7.46%
1 Month
+4.08%
+4.08%
3 Month
+2.57%
+2.57%
6 Month
+0.03%
+0.03%
1 Year
-10.75%
-10.75%
More News
Read More
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
December 07, 2023
Via
SBWire
A Look Into Gilead Sciences Inc's Price Over Earnings
December 07, 2023
Via
Benzinga
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
December 07, 2023
Via
InvestorPlace
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today
December 06, 2023
Via
Benzinga
Looking Into Gilead Sciences's Recent Short Interest
November 22, 2023
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
November 21, 2023
Via
Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making
November 30, 2023
Via
InvestorPlace
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
November 30, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 30, 2023
Via
The Motley Fool
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Via
Benzinga
Exposures
Product Safety
J&J, Gilead, BMS: A look at undervalued dividend payers
November 29, 2023
Via
MarketBeat
Is NASDAQ:GILD suited for dividend investing?
November 20, 2023
Via
Chartmill
Gilead Sciences's Options: A Look at What the Big Money is Thinking
November 15, 2023
Via
Benzinga
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
November 26, 2023
Via
The Motley Fool
Stocks Stall On November 21, 2023, As Systematic Flows Abate
November 21, 2023
Via
Talk Markets
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
November 17, 2023
Via
Benzinga
Exposures
Product Safety
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals.
November 17, 2023
Via
Chartmill
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
November 15, 2023
Via
Investor's Business Daily
A Closer Look at Gilead Sciences's Options Market Dynamics
November 09, 2023
Via
Benzinga
Where Gilead Sciences Stands With Analysts
November 09, 2023
Via
Benzinga
Kite and Arcellx Announce Expansion in Strategic Partnership
November 15, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
Via
Investor's Business Daily
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
November 09, 2023
Via
FinancialNewsMedia
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.